Skip to main content

Table 5 Logistic regression estimates for the association between microvessel density (MVD) and breast biopsy diagnosis stratified by mammographic density (MD) measures

From: Relationships between mammographic density, tissue microvessel density, and breast biopsy diagnosis

Density measure

Below median of mammographic density measure

Above median of mammographic density measure

 
 

Cases

Non-cases

OR (95 % CI)a

Cases

Non-cases

OR (95 % CI)a

P heterogeneityb

Volume

Effect of microvessel density (MVD)c on breast cancer risk

 

Global

       

 % density (volume)

23

87

2.35 (1.33–4.14)

21

87

1.23 (0.73–2.07)

0.11

 Dense volume (cm3)

22

87

1.60 (0.84–3.05)

22

87

1.78 (1.07–2.98)

0.23

 Non-dense volume (cm3)

21

87

1.14 (0.67–1.95)

23

87

2.51 (1.41–4.46)

0.08

Lesional

       

 % dense volume (cm3)

21

88

3.03 (1.61–5.70)

23

86

1.10 (0.69–1.79)

0.03

 Dense volume (cm3)

19

88

1.25 (0.67–2.32)

25

86

1.90 (1.15–3.13)

0.61

 Non-dense volume (cm3)

15

87

0.97 (0.50–1.90)

29

87

2.13 (1.30–3.48)

0.06

  1. Each MD measure was dichotomized at the median based on the distribution among non-cases. ORs with P values < 0.05 are presented in bold font. Non-cases: non-proliferative benign breast disease, proliferative (ductal hyperplasia; sclerosing adenosis), proliferative with atypia (atypical ductal or lobular hyperplasia). Cases: ductal or lobular carcinoma in situ and invasive cancer
  2. aAdjusted for age at biopsy (39–44, 45–49, 50–54, 55–59, 60–65 years) and BMI (<25, 25– < 30, 30+ kg/m2)
  3. b P heterogeneity based on a Wald test in the regression model corresponding to an interaction term between the dichotomous MD measure and MVD
  4. cThe average of MVD within a woman was computed and standardized by one standard deviation